Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI)

<div>34-year-old woman. Invasive ductal carcinoma with progressive disease. Segmental non-mass enhancement is detected in the lower inner quadrant of the left breast on contrast-enhanced mammography (a) and magnetic resonance imaging (c) before NAC. After NAC, a diffuse non-mass enhancement is detected on CEM (b) and MRI (d).</div>

BioMed Research International

fig3

Figure 3

Figure 3: Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) 

Figure 3 | Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) 